Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
doi: 10.1016/j.jchromb.2023.123742
Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP1 and amylin analogues owenhaskins Dec 19, 2025 2 min read Novo Nordisk has submitted a New Drug Application (NDA) to the FDA for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection, to be used with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition
However, there are important caveats
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a highly selective thyroid hormone receptor agonist in clinical trials for the treatment of dyslipidemia
US$ 29.91
US$ 24.05
US$ 26.75
US$ 29.32
US$ 26.34
US$ 24.79
US$ 24.63
US$ 26.89
US$ 27.63
US$ 21.06
US$ 20.36
